ADMA up 3% premarket on FDA OK of license transfers

ADMA Biologics (NASDAQ:ADMA) is up 3% premarket on average volume in reaction to the FDA’s signoff for the transfer of licenses for BIVIGAM and Nabi-HB from Biotest Pharmaceuticals to the company.

The license transfers were the final regulatory items from its acquisition of Biotest’s Therapy Business Unit in June 2017.

https://seekingalpha.com/news/3476168-adma-3-percent-premarket-fda-ok-license-transfers